An open-label randomized parallel-group phase I study of the oral Bruton tyrosine kinase inhibitor tirabrutinib in systemic sclerosis
This study suggests that tirabrutinib is tolerable in patients with SSc and acts by suppressing B-cell activity.
Authors
- Ayumi Yoshizaki (ORCID: https://orcid.org/0000-0002-8194-9140)
- Masaaki Doi (ORCID: https://orcid.org/0000-0002-0829-8273)
- Toshiro Io (ORCID: https://orcid.org/0000-0001-9467-5030)
- Tomohiro Harada (ORCID: https://orcid.org/0000-0002-0704-4351)
- Minoru Hasegawa (ORCID: https://orcid.org/0000-0003-3738-2682)
- Kazuki Matsuda
- Akira Kitani (ORCID: https://orcid.org/0000-0003-1781-373X)
- Shinichi Sato (ORCID: https://orcid.org/0000-0001-5519-172X)
Institutions
- University of Fukui (JP)
- University of Tokyo Hospital (JP)
- Ono Pharmaceutical (Japan) (JP)
- Drug Discovery Laboratory (Norway) (NO)
- The University of Tokyo (JP)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-07-30
- DOI
- https://doi.org/10.1093/bjd/ljaf168
- Citations
- 2
- Primary Topic
- Systemic Sclerosis and Related Diseases
- Type
- article
- Field-Weighted Citation Impact
- 2.94
Funders
- Ono Pharmaceutical